# En Carta Diagnostics **Source:** https://www.startuphub.ai/startups/en-carta-diagnostics **Profile type:** Startup > Developing a new generation of molecular diagnostics for at-home use, combining laboratory accuracy with rapid test simplicity. ## About En Carta Diagnostics is a Paris-based DeepTech startup focused on revolutionizing molecular diagnostics by making them accessible for at-home use. Their proprietary platform aims to deliver the precision of laboratory PCR tests with the ease of use of rapid tests, providing results in approximately 30 minutes. The company is initially targeting early detection of Lyme disease and expanding into STI screening. Their technology utilizes aptamers for high-affinity and specific target binding, allowing for a wide range of applications. En Carta Diagnostics is working towards regulatory certification in Europe and the US, industrializing production through a fabless model, and accelerating commercial launch. ## Key facts - **Slug:** en-carta-diagnostics - **Website:** https://encartadiagnostics.com/ - **Location:** Paris, France - **Founded:** 2022-01-01 - **Employees:** 12 - **Operating status:** Inactive - **Total funding:** $5M - **Sectors / tags:** Biotechnology, HealthTech, Diagnostics, Medical Devices, MedTech, Biotech, Molecular Diagnostics, At-Home Testing, Deep Tech - **Social:** - LinkedIn: https://www.linkedin.com/company/en-carta-diagnostics/ ## Frequently asked ### What does En Carta Diagnostics do? En Carta Diagnostics is a Paris-based DeepTech startup focused on revolutionizing molecular diagnostics by making them accessible for at-home use. Their proprietary platform aims to deliver the precision of laboratory PCR tests with the ease of use of rapid tests, providing results in approximately 30 minutes. The company is initially targeting early detection of Lyme disease and expanding into STI screening. Their technology utilizes aptamers for high-affinity and specific target binding, allow… ### What is En Carta Diagnostics's revenue? StartupHub estimates En Carta Diagnostics's annual revenue at $1.3M (range $774K to $4.1M, 69% confidence), based on comparable companies in the sector. ### What is En Carta Diagnostics's valuation? StartupHub estimates En Carta Diagnostics's effective valuation at $20.2M (range $12.5M to $30.0M, 24% confidence), based on comparable companies in the sector. ### How much funding has En Carta Diagnostics raised? En Carta Diagnostics has raised a total of $5M in funding. The most recent round on record is Seed. ### Where is En Carta Diagnostics headquartered? En Carta Diagnostics is headquartered in Paris, France. ### When was En Carta Diagnostics founded? En Carta Diagnostics was founded in 2022. ### What industry does En Carta Diagnostics operate in? En Carta Diagnostics operates in Biotechnology, HealthTech, Diagnostics, Medical Devices, MedTech, Biotech. ### How many employees does En Carta Diagnostics have? En Carta Diagnostics has approximately 12 people on record. ### What is En Carta Diagnostics's current status? En Carta Diagnostics's current operating status is: Inactive. ## JSON-LD Structured data aligned with this page's `